Literature DB >> 11873320

A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents.

Annick Raas-Rothschild1, Ronald J A Wanders, Petra A W Mooijer, Jeannette Gootjes, Hans R Waterham, Alisa Gutman, Yasuyuki Suzuki, Nobuyuki Shimozawa, Naomi Kondo, Gideon Eshel, Marc Espeel, Frank Roels, Stanley H Korman.   

Abstract

Sensorineural deafness and retinitis pigmentosa (RP) are the hallmarks of Usher syndrome (USH) but are also prominent features in peroxisomal biogenesis defects (PBDs); both are autosomal recessively inherited. The firstborn son of unrelated parents, who both had sensorineural deafness and RP diagnosed as USH, presented with sensorineural deafness, RP, dysmorphism, developmental delay, hepatomegaly, and hypsarrhythmia and died at age 17 mo. The infant was shown to have a PBD, on the basis of elevated plasma levels of very-long- and branched-chain fatty acids (VLCFAs and BCFAs), deficiency of multiple peroxisomal functions in fibroblasts, and complete absence of peroxisomes in fibroblasts and liver. Surprisingly, both parents had elevated plasma levels of VLCFAs and BCFAs. Fibroblast studies confirmed that both parents had a PBD. The parents' milder phenotypes correlated with relatively mild peroxisomal biochemical dysfunction and with catalase immunofluorescence microscopy demonstrating mosaicism and temperature sensitivity in fibroblasts. The infant and both of his parents belonged to complementation group C. PEX6 gene sequencing revealed mutations on both alleles, in the infant and in his parents. This unique family is the first report of a PBD with which the parents are themselves affected individuals rather than asymptomatic carriers. Because of considerable overlap between USH and milder PBD phenotypes, individuals suspected to have USH should be screened for peroxisomal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11873320      PMCID: PMC379104          DOI: 10.1086/339766

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  31 in total

Review 1.  Genotype-phenotype correlations in disorders of peroxisome biogenesis.

Authors:  H W Moser
Journal:  Mol Genet Metab       Date:  1999-10       Impact factor: 4.797

2.  Characteristic urine organic acid profile in peroxisomal biogenesis disorders.

Authors:  S H Korman; H Mandel; A Gutman
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

3.  The peroxin Pex6p gene is impaired in peroxisomal biogenesis disorders of complementation group 6.

Authors:  N Matsumoto; S Tamura; A Moser; H W Moser; N Braverman; Y Suzuki; N Shimozawa; N Kondo; Y Fujiki
Journal:  J Hum Genet       Date:  2001       Impact factor: 3.172

Review 4.  Clinical, biochemical and genetic aspects and neuronal migration in peroxisome biogenesis disorders.

Authors:  Y Suzuki; N Shimozawa; A Imamura; S Fukuda; Z Zhang; T Orii; N Kondo
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 5.  Peroxisome biogenesis disorders: genetics and cell biology.

Authors:  S J Gould; D Valle
Journal:  Trends Genet       Date:  2000-08       Impact factor: 11.639

6.  Diagnosis and follow-up of a case of peroxisomal disorder with peroxisomal mosaicism.

Authors:  M Pineda; M Girós; F Roels; M Espeel; M Ruiz; A Moser; H W Moser; R J Wanders; C Pavia; J Conill; A Aracil; L Amat; T Pampols
Journal:  J Child Neurol       Date:  1999-07       Impact factor: 1.987

7.  Temperature-sensitive mutation of PEX6 in peroxisome biogenesis disorders in complementation group C (CG-C): comparative study of PEX6 and PEX1.

Authors:  A Imamura; N Shimozawa; Y Suzuki; Z Zhang; T Tsukamoto; Y Fujiki; T Orii; T Osumi; R J Wanders; N Kondo
Journal:  Pediatr Res       Date:  2000-10       Impact factor: 3.756

8.  The peroxisome biogenesis factors pex4p, pex22p, pex1p, and pex6p act in the terminal steps of peroxisomal matrix protein import.

Authors:  C S Collins; J E Kalish; J C Morrell; J M McCaffery; S J Gould
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

Review 9.  Usher syndrome: from genetics to pathogenesis.

Authors:  C Petit
Journal:  Annu Rev Genomics Hum Genet       Date:  2001       Impact factor: 8.929

10.  Ophthalmic manifestations of infantile phytanic acid storage disease.

Authors:  R G Weleber; A C Tongue; N G Kennaway; S S Budden; N R Buist
Journal:  Arch Ophthalmol       Date:  1984-09
View more
  23 in total

1.  Deep sequencing reveals 50 novel genes for recessive cognitive disorders.

Authors:  Hossein Najmabadi; Hao Hu; Masoud Garshasbi; Tomasz Zemojtel; Seyedeh Sedigheh Abedini; Wei Chen; Masoumeh Hosseini; Farkhondeh Behjati; Stefan Haas; Payman Jamali; Agnes Zecha; Marzieh Mohseni; Lucia Püttmann; Leyla Nouri Vahid; Corinna Jensen; Lia Abbasi Moheb; Melanie Bienek; Farzaneh Larti; Ines Mueller; Robert Weissmann; Hossein Darvish; Klaus Wrogemann; Valeh Hadavi; Bettina Lipkowitz; Sahar Esmaeeli-Nieh; Dagmar Wieczorek; Roxana Kariminejad; Saghar Ghasemi Firouzabadi; Monika Cohen; Zohreh Fattahi; Imma Rost; Faezeh Mojahedi; Christoph Hertzberg; Atefeh Dehghan; Anna Rajab; Mohammad Javad Soltani Banavandi; Julia Hoffer; Masoumeh Falah; Luciana Musante; Vera Kalscheuer; Reinhard Ullmann; Andreas Walter Kuss; Andreas Tzschach; Kimia Kahrizi; H Hilger Ropers
Journal:  Nature       Date:  2011-09-21       Impact factor: 49.962

2.  A novel PEX12 mutation identified as the cause of a peroxisomal biogenesis disorder with mild clinical phenotype, mild biochemical abnormalities in fibroblasts and a mosaic catalase immunofluorescence pattern, even at 40 degrees C.

Authors:  Avraham Zeharia; Merel S Ebberink; Ronald J A Wanders; Hans R Waterham; Alisa Gutman; Andreea Nissenkorn; Stanley H Korman
Journal:  J Hum Genet       Date:  2007-05-30       Impact factor: 3.172

3.  Lymphoblastoid cell lines for diagnosis of peroxisome biogenesis disorders.

Authors:  Sabine Grønborg; Ralph Krätzner; Hendrik Rosewich; Jutta Gärtner
Journal:  JIMD Rep       Date:  2011-06-22

4.  Clinical utility gene card for: Zellweger syndrome spectrum.

Authors:  Hendrik Rosewich; Hans Waterham; Bwee Tien Poll-The; Andreas Ohlenbusch; Jutta Gärtner
Journal:  Eur J Hum Genet       Date:  2014-11-19       Impact factor: 4.246

5.  Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.

Authors:  Rui Zhang; Li Chen; Sarn Jiralerspong; Ann Snowden; Steven Steinberg; Nancy Braverman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

6.  Mild Zellweger syndrome due to a novel PEX6 mutation: correlation between clinical phenotype and in silico prediction of variant pathogenicity.

Authors:  Małgorzata Rydzanicz; Teresa Joanna Stradomska; Elżbieta Jurkiewicz; Ewa Jamroz; Piotr Gasperowicz; Grażyna Kostrzewa; Rafał Płoski; Anna Tylki-Szymańska
Journal:  J Appl Genet       Date:  2017-10-18       Impact factor: 3.240

7.  A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts.

Authors:  S J Steinberg; A Snowden; N E Braverman; L Chen; P A Watkins; P T Clayton; K D R Setchell; J E Heubi; G V Raymond; A B Moser; H W Moser
Journal:  J Inherit Metab Dis       Date:  2008-12-25       Impact factor: 4.982

8.  Two novel mutations of PEX6 in one Chinese Zellweger spectrum disorder and their clinical characteristics.

Authors:  Hui-Ling Yu; Yan Shen; Yi-Min Sun; Yue Zhang
Journal:  Ann Transl Med       Date:  2019-08

9.  Deletion of a single allele of the Pex11β gene is sufficient to cause oxidative stress, delayed differentiation and neuronal death in mouse brain.

Authors:  Barbara Ahlemeyer; Magdalena Gottwald; Eveline Baumgart-Vogt
Journal:  Dis Model Mech       Date:  2011-10-04       Impact factor: 5.758

Review 10.  Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2.

Authors:  M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan
Journal:  Hum Genet       Date:  2021-07-30       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.